Posted: Tue Jan 20, 2009 9:15 am Post subject: DAS181 Fludase Completes Phase 1
The study drug was well tolerated at all dose levels.
DAS181 is a novel broad-spectrum drug candidate for prophylaxis and treatment of respiratory infections by all variations of influenza virus, including the types of the virus that may cause a potential influenza pandemic. In addition, DAS181 also has the potential for prophylaxis and treatment of influenza-like illness due to other respiratory viruses, including the parainfluenza virus which may cause serious respiratory illness similar to influenza for which there is no approved vaccine or therapeutic. The DAS181 development program is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
DAS181, a recombinant fusion protein, inactivates viral receptors on the cells of the human respiratory tract, thereby preventing influenza and parainfluenza viruses from infecting the human body or from amplifying in infected individuals.
DAS181 effectively inhibits numerous strains of influenza and parainfluenza virus in cell culture and in animal models. Unlike current antiviral compounds and vaccines, DAS181 targets human host receptors, not virus components, and thus carries a reduced risk of drug resistance compared with the currently available antiviral drugs. Extensive, prolonged nonclinical studies have not shown the development of any meaningful resistance.
Full story http://www.medicalnewstoday.com/articles/135979.php _________________ https://twitter.com/mixin1771
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum